Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Superluminal Medicines Announces The Closing Of An Oversubscribed $60 Million Series B Financing Led By Bvf Partners, L.P. To Advance Its Lead Program In Rare Genetic Forms Of Obesity Into Clinical Trials. announced it raised $65.5 Million in an initial filing from an offering of $65.5 Million

PRIVATESep 03, 2026•5 days ago

Amount Raised

$65.5 Million

Round Type

Series B

BostonBiotechnologyHealth Care

Investors

GaingelsCooleyEli Lilly And CompanyCatalio Capital ManagementNvidiaInsight PartnersRa Capital ManagementPerceptive AdvisorsDeep Track CapitalBvf Partners, L.P.

Description

Superluminal Medicines, a biotechnology company, has closed an oversubscribed $60 million Series B financing. The proceeds will support the initiation of a Phase 1 clinical trial for rare genetic forms of obesity by the end of 2026. The financing was led by BVF Partners, L.P., with participation from Deep Track Capital, Perceptive Advisors, and existing investors. This marks a significant milestone as the company transitions to a clinical-stage biotechnology company.

Company Information

Company

Superluminal Medicines

Location

Boston, Massachusetts, United States

About

Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.

Don't miss Superluminal Medicines's next move

Get an email the moment Superluminal Medicines raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Related People

Suggested for you
2 contacts
Predictive Intelligence
Strategic

ML-powered predictions for Superluminal Medicines's next move

See what Strategic adds

Funding Insights

Based on industry data
Timeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Superluminal Medicines raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.